NASD · Healthcare · Biotechnology · USA
Absci Corp is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
Absci is a clinical-stage biopharmaceutical company developing antibody therapeutics using an AI-native platform that combines generative design with laboratory validation. The company is advancing its lead candidate for androgenetic alopecia and endometriosis, alongside preclinical programs, and pursues partnerships to monetize select pipeline assets.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Absci Corp stock.
Overvalued: intrinsic value $0.72 per share, market price $8.54, margin of safety -1094.2% (as of 2026-10-19).
Its liquidation floor, current assets minus every liability, values the shares at $0.72; the price of $8.54 is 1094% above that value.
17 more funds hold it; the full list is part of the paid plan.
119 more in this industry show a wider margin of safety.
ABSI is overvalued (as of the 2026-10-19 close). Its liquidation floor, current assets minus every liability, values the shares at $0.72; the price of $8.54 is 1094% above that value.
$0.72 per share (as of the 2026-10-19 close), against a market price of $8.54. That is a margin of safety of -1094.2%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.